H.C. Wainwright analyst Edward White maintained a Buy rating on Celyad (CYAD) today and set a price target of $17.00. The company’s shares closed last Friday at $5.67, close to its 52-week low of $5.27.
According to TipRanks.com, White is a 5-star analyst with an average return of 40.1% and a 46.0% success rate. White covers the Healthcare sector, focusing on stocks such as Spectrum Pharmaceuticals, Karyopharm Therapeutics, and Silverback Therapeutics.
Celyad has an analyst consensus of Moderate Buy, with a price target consensus of $17.00, implying a 193.6% upside from current levels. In a report issued on May 6, William Blair also maintained a Buy rating on the stock.
See today’s analyst top recommended stocks >>
The company has a one-year high of $13.01 and a one-year low of $5.27. Currently, Celyad has an average volume of 26.64K.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Celyad SA is a clinical-stage biopharmaceutical company, which engages in the development of cell-based therapies for the treatment of cancer. It operates through the following segments: Cardiology, Immuno-oncology, and Corporate. The Cardiology segment includes the company’s Cardiopoiesis, Corquest, and C-Cathez platforms. The Immuno-oncology segment consists of all assets developed based on the CAR-T cell platform. The company was founded by Michel Lussier, William Wijns, and Christian Homsy on July 24, 2007 and is headquartered in Mont-Saint-Guibert, Belgium.
